BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics firm focused on early cancer detection, has announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank for the German state of Rheinland-Pfalz.

The state will finance up to 50% of the project’s total expenses through the ISB’s Innovation and Technology Support Program (Innovations- und Technologieförderungsprogramm). This direct government funding highlights the scientific and societal significance of Mainz Biomed’s non-invasive, blood-based screening test for the early identification of pancreatic cancer and will help speed up its development.

The grant highlights the medical and technological importance of Mainz Biomed’s strategy. The project seeks to address a significant gap in cancer diagnostics by enabling the detection of pancreatic cancer at an earlier, more treatable stage.

“This ISB support is a strong indication of confidence in our technology’s potential and the crucial role of early detection in the fight against pancreatic cancer,” stated Dr. Moritz Eidens, CSO of Mainz Biomed.

The project is currently in the feasibility stage. Mainz Biomed, along with Crown Bioscience, is assessing the effectiveness of a panel of mRNA biomarkers and a machine learning (ML) algorithm, utilizing actual clinical blood samples. This effort is part of the Company’s broader strategy to broaden its range of accessible, non-invasive diagnostics for various cancer types.

Please follow us to stay up to date:

About Mainz Biomed NV
Mainz Biomed develops ready-to-market molecular genetic diagnostic solutions for life-threatening diseases. The Company’s primary product is ColoAlert®, a precise, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is available across Europe and the United Arab Emirates. The Company is currently conducting a pivotal FDA clinical study for regulatory approval in the US. Mainz Biomed’s product pipeline also includes PancAlert, an early-stage pancreatic cancer screening test that uses real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit or follow us on , and .

For media inquiries
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20

For investor inquiries, please contact

Forward-Looking Statements
Certain statements in this press release are “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995’s “safe harbor” provisions. These statements can be identified by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” as well as similar expressions that predict or suggest future events or trends, or that do not relate to historical facts. These forward-looking statements represent the current analysis of available information and are subject to various risks and uncertainties. Consequently, caution should be exercised when relying on them. Actual results may significantly differ from the Company’s expectations or projections due to known and unknown risks. Factors that could cause actual results to differ materially include: (i) failure to achieve projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties detailed herein, as well as those discussed periodically in the Company’s reports and other public filings with the Securities and Exchange Commission (the “SEC”). Additional information on these and other factors that may affect the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025. The Company’s SEC filings are publicly available on the SEC’s website at www.sec.gov. Any forward-looking statement in this press release is based solely on information currently available to Mainz Biomed and is made only as of the date it is issued. Mainz Biomed undertakes no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether because of new information, future developments, or otherwise, except as required by law.